Trial Profile
A Phase I Dose-Escalation First-In-Human Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral MEK Inhibitor MSC2015103B Administered with (EMR200064-001)Two Different Treatment Schedules in Subjects with Advanced Solid Tumors.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs MSC 2015103B (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors EMD Serono
- 27 Mar 2017 Status changed from completed to discontinued.
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Dec 2011 New source identified and integrated (Barbara Ann Karmanos Cancer Institute: 2011-088).